Two-year (yr) follow-up (FU) of Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL) Meeting Abstract
| Authors: | Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M.; Wang, M.; Arnason, J.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A. R.; Solomon, S. R.; Ghosh, N.; Kostic, A.; Kim, Y.; Ogasawara, K.; Dehner, C.; Siddiqi, T. |
| Abstract Title: | Two-year (yr) follow-up (FU) of Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL) |
| Meeting Title: | 2022 Tandem Meetings of ASTCT and CIBMTR |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 28 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2022 Apr 23-26 |
| Meeting Location: | Salt Lake City, UT |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-03-01 |
| Start Page: | S55 |
| End Page: | S56 |
| DOI: | 10.1016/S2666-6367(22)00226-3 |
| PROVIDER: | manual |
| Notes: | Abstract: 65 -- Located within the section named "Oral Abstract - Session H - Car-T - Session I" |
